Skip to main content

CORRECTION article

Front. Immunol., 31 August 2022
Sec. Immunological Memory
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1018384

Corrigendum: ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk

This article is a correction to:

  1. ACTIVATE-2: A Double-Blind Randomized Trial of BCG Vaccination Against COVID-19 in Individuals at Risk

    1. Read original article
Maria TsilikaMaria Tsilika1Esther TaksEsther Taks2Konstantinos DolianitisKonstantinos Dolianitis3Antigone KotsakiAntigone Kotsaki1Konstantinos LeventogiannisKonstantinos Leventogiannis1Christina DamoulariChristina Damoulari1Maria KostoulaMaria Kostoula1Maria PanetaMaria Paneta1Georgios AdamisGeorgios Adamis4Ilias PapanikolaouIlias Papanikolaou5Kimon StamatelopoulosKimon Stamatelopoulos6Amalia BolanouAmalia Bolanou1Konstantinos KatsarosKonstantinos Katsaros7Christina DelaviniaChristina Delavinia6Ioannis PerdiosIoannis Perdios4Aggeliki PandiAggeliki Pandi5Konstantinos TsiakosKonstantinos Tsiakos8Nektarios ProiosNektarios Proios1Emmanouela KalogianniEmmanouela Kalogianni6Ioannis DelisIoannis Delis9Efstathios SklirosEfstathios Skliros10Karolina AkinosoglouKarolina Akinosoglou11Aggeliki PerdikouliAggeliki Perdikouli1Garyfallia PoulakouGaryfallia Poulakou8Haralampos MilionisHaralampos Milionis12Eva AthanassopoulouEva Athanassopoulou1Eleftheria KalpakiEleftheria Kalpaki1Leda EfstratiouLeda Efstratiou13Varvara PerrakiVarvara Perraki13Antonios PapadopoulosAntonios Papadopoulos1Mihai G. Netea,&#x;Mihai G. Netea2,14†Evangelos J. Giamarellos-Bourboulis,*&#x;Evangelos J. Giamarellos-Bourboulis1,13*†
  • 14thDepartment of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece
  • 2Department of Internal Medicine and Center for Infectious Diseases, Radboud University, Nijmegen, Netherlands
  • 3Department of Internal Medicine, “Bodosakeio” General Hospital of Ptolemaida, Ptolemaida, Greece
  • 41stDepartment of Internal Medicine, “G.Gennimatas” Athens General Hospital, Athens, Greece
  • 5Department of Pulmonary Medicine, Aghia Eirini General Hospital of Kerkyra, Kontokali, Greece
  • 6Department of Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
  • 7Department of Surgery, General Hospital of Argos-Unit of Nafplion, Nafplion, Greece
  • 83rdDepartment of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece
  • 9Department of Internal Medicine, General Hospital of Karditsa, Karditsa, Greece
  • 10Nemea Health Center, Nemea, Greece
  • 11Department of Internal Medicine, Patras University Hospital, Rio, Greece
  • 121stDepartment of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece
  • 13Hellenic Institute for the Study of Sepsis, Athens, Greece
  • 14Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany

A Corrigendum on
ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk.

by Tsilika M, Taks E, Dolianitis K, Kotsaki A, Leventogiannis K, Damoulari C, Kostoula M, Paneta M, Adamis G, Papanikolaou I, Stamatelopoulos K, Bolanou A, Katsaros K, Delavinia C, Perdios I, Pandi A, Tsiakos K, Proios N, Kalogianni E, Delis I, Skliros E, Akinosoglou K, Perdikouli A, Poulakou G, Milionis H, Athanassopoulou E, Kalpaki E, Efstratiou L, Perraki V, Papadopoulos A, Netea MG and Giamarellos-Bourboulis EJ (2022). Front. Immunol. 13:873067. doi: 10.3389/fimmu.2022.873067

In the published article, there were errors in the body text.

A correction has been made to the Abstract. This sentence previously stated:

“These data indicate that BCG vaccination confers some protection against possible COVID-19 among patients older than 50 years with comorbidities.”

The corrected sentence appears below:

“The ACTIVATE II trial did not meet the primary endpoint of the reduction of the risk for COVID-19 3 months after BCG vaccination; however, the secondary endpoint of the reduction of the risk for COVID-19 6 months after BCG vaccination was met.”

A correction has also been made to Results, Study End Points, paragraph 1. This sentence previously stated:

“During these first 3 months after the vaccination the overall incidence of COVID-19 in Greece was low, and thus the number of COVID-19 diagnoses was low in both groups (10 patients in placebo vs. two participants in BCG group, p=0.086.”

The corrected sentence appears below:

“The primary endpoint was met in 10 participants in the placebo group and two participants in the BCG group (p= 0.086). This may be due to the low overall incidence of COVID-19 in Greece the first 3 months after the vaccination.”

A correction has also been made to Discussion, paragraph 1. This sentence previously stated:

“BCG vaccination resulted in a substantially lower incidence of possible/probable/definitive COVID-19 in an elderly population 6-months after vaccination, than in the placebo group.”

The corrected sentence appears below:

“Although the primary endpoint of the decrease of the incidence of possible/probable/definitive COVID-19 3-months after vaccination was not met, the trial managed to achieve the secondary endpoint and demonstrate lower incidence of possible/probable/definitive COVID-19 in a population with comorbidities 6-months after vaccination.”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: BCG, COVID-19, SARS-CoV-2, elderly vaccination, trained immunity

Citation: Tsilika M, Taks E, Dolianitis K, Kotsaki A, Leventogiannis K, Damoulari C, Kostoula M, Paneta M, Adamis G, Papanikolaou I, Stamatelopoulos K, Bolanou A, Katsaros K, Delavinia C, Perdios I, Pandi A, Tsiakos K, Proios N, Kalogianni E, Delis I, Skliros E, Akinosoglou K, Perdikouli A, Poulakou G, Milionis H, Athanassopoulou E, Kalpaki E, Efstratiou L, Perraki V, Papadopoulos A, Netea MG and Giamarellos-Bourboulis EJ (2022) Corrigendum: ACTIVATE-2: A double-blind randomized trial of BCG vaccination against COVID-19 in individuals at risk. Front. Immunol. 13:1018384. doi: 10.3389/fimmu.2022.1018384

Received: 13 August 2022; Accepted: 15 August 2022;
Published: 31 August 2022.

Edited and Reviewed by:

Peter Katsikis, Erasmus University Rotterdam, Netherlands

Copyright © 2022 Tsilika, Taks, Dolianitis, Kotsaki, Leventogiannis, Damoulari, Kostoula, Paneta, Adamis, Papanikolaou, Stamatelopoulos, Bolanou, Katsaros, Delavinia, Perdios, Pandi, Tsiakos, Proios, Kalogianni, Delis, Skliros, Akinosoglou, Perdikouli, Poulakou, Milionis, Athanassopoulou, Kalpaki, Efstratiou, Perraki, Papadopoulos, Netea and Giamarellos-Bourboulis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Evangelos J. Giamarellos-Bourboulis, egiamarel@med.uoa.gr

†These authors share senior authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.